Acura Pharmaceuticals, Inc. announced today William A. Sumner has retired as a member of our Board of Directors and affiliated subsidiary after 14 years of service. Mr. Sumner has agreed to serve as Director Emeritus following his resignation. In such capacity, Mr. Sumner may attend Board and Committee meetings and participate in the discussion of matters at such meetings, but he will not have voting rights on any such matters.Mr. Sumner has been a member of our Board of Directors since August, 1997 and joined after a long and distinguished career in the pharmaceutical industry. From 1974 until his retirement in 1995, Mr. Sumner held various positions within Hoechst-Roussel Pharmaceuticals, Inc., including Vice President and General Manager, Dermatology Division from 1991 through 1995, Vice President, Strategic Business Development, from 1989 to 1991 and Vice President, Marketing from 1985 to 1989. Since his retirement from Hoechst-Roussel Pharmaceuticals, Inc. in 1995, Mr. Sumner has served as a consultant in the pharmaceutical industry.As a member of Acura's Board, Mr. Sumner helped to oversee the transformation of Acura from a troubled generic pharmaceutical manufacturer to a branded specialty pharmaceutical company engaged in research of proprietary technologies to address the abuse and misuse of pharmaceutical products.Remarking on the Mr. Sumner's retirement, Richard Markham, Chairman of the Board stated, "We are very grateful to Bill for his many years of outstanding service to the Company. Bill's willingness to serve as Director Emeritus will allow the Board to continue to avail itself of his wisdom, judgment and experience."The vacancy on our Board created by Mr. Sumner's retirement will remain until the Board appoints a successor.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment